Aboubakar M, Puisieux F, Couvreur P, Deyme M, Vauthier C
UMR 8612, Université de Paris XI, Faculté de Pharmacie, 5 rue J.B. Clément, 92 296 Chatenay Malabry Cedex, France.
J Biomed Mater Res. 1999 Dec 15;47(4):568-76. doi: 10.1002/(sici)1097-4636(19991215)47:4<568::aid-jbm14>3.0.co;2-x.
In previous studies, insulin-loaded poly(alkylcyanoacrylate) nanocapsules were found to reduce the blood glucose level after oral administration to diabetic rats and dogs. The reduction of the glycemia induced by the nanocapsules was the same regardless of the insulin doses administered, but the effect appeared only after a delay of a few days. The purpose of this study was to investigate the mechanism of insulin encapsulation and the type of interactions that may exist between the polymer forming the nanocapsule wall and the insulin. The results of this study showed, based on the interfacial polymerization of isobutylcyanoacrylate, that the insulin molecule is not chemically modified during the nanoencapsulation process. In addition, no interaction between the poly(isobutylcyanoacrylate) and the insulin could be observed. The observed high encapsulation efficiency of intact insulin may be explained by the fact that the ethanol used in the preparation of the nanocapsules is responsible for the initiation of the interfacial polymerization of isobutylcyanoacrylate instead of the insulin. The zeta potential measurements suggest that insulin is located within the core of the nanocapsules. Thus the biological activity of the nanoencapsulated peptide and the high efficiency of insulin encapsulation achieved with this nanoencapsulation process cannot be explained by a specific interaction of the insulin with the polymer forming the nanocapsule's wall. It may be due, however, to the fact that the encapsulated insulin molecule is chemically intact and located within the oily core of the nanocapsules.
